Merck & Co., Inc. $MRK Shares Acquired by Roffman Miller Associates Inc. PA

Roffman Miller Associates Inc. PA increased its position in shares of Merck & Co., Inc. (NYSE:MRK) by 2.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 205,225 shares of the company’s stock after purchasing an additional 5,226 shares during the quarter. Roffman Miller Associates Inc. PA’s holdings in Merck & Co., Inc. were worth $16,246,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of MRK. Vanguard Group Inc. raised its stake in shares of Merck & Co., Inc. by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 252,513,381 shares of the company’s stock worth $22,665,601,000 after buying an additional 1,417,274 shares during the last quarter. Wellington Management Group LLP increased its holdings in Merck & Co., Inc. by 1.1% during the 1st quarter. Wellington Management Group LLP now owns 81,669,651 shares of the company’s stock valued at $7,330,668,000 after acquiring an additional 927,621 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Merck & Co., Inc. by 144.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company’s stock worth $4,418,820,000 after acquiring an additional 29,104,112 shares during the last quarter. Amundi lifted its holdings in shares of Merck & Co., Inc. by 37.1% in the first quarter. Amundi now owns 13,077,716 shares of the company’s stock valued at $1,130,397,000 after purchasing an additional 3,542,036 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Merck & Co., Inc. in the first quarter valued at about $991,553,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 4.0%

Shares of MRK opened at $82.51 on Tuesday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $105.07. The company has a market capitalization of $206.09 billion, a PE ratio of 12.71, a price-to-earnings-growth ratio of 0.95 and a beta of 0.37. The stock has a fifty day moving average of $84.51 and a two-hundred day moving average of $81.89. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, October 30th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.36 by $0.22. The business had revenue of $17.28 billion during the quarter, compared to the consensus estimate of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.57 earnings per share. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Wall Street Analyst Weigh In

MRK has been the subject of several research reports. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their price objective for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. Morgan Stanley raised their price target on Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research report on Monday. Citigroup began coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They issued a “neutral” rating and a $95.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company cut their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 30th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $104.47.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.